DUBLIN--(BUSINESS WIRE)--The "Aurora Kinase B - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) pipeline Target constitutes close to 16 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes.
Scope
- The report provides a snapshot of the global therapeutic landscape for Aurora Kinase B
- The report reviews Aurora Kinase B targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Aurora Kinase B targeted therapeutics and enlists all their major and minor projects
- The report assesses Aurora Kinase B targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Aurora Kinase B targeted therapeutics
Companies Featured
- AbbVie Inc
- Advenchen Laboratories LLC
- Aeterna Zentaris Inc
- Amgen Inc
- AstraZeneca Plc
- Chipscreen Biosciences Ltd
- Cielo Therapeutics Inc
- Merck & Co Inc
- Sanofi
- Sareum Holdings Plc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/k693v5/aurora_kinase_b?w=4